Literature DB >> 21197371

Symptom control and patient adherence to treatment: key goals in the treatment of psychosis.

Marios Adamou1.   

Abstract

A CLINICIAN'S KEY GOALS WHEN TREATING PSYCHOSIS ARE TO control disease symptoms and to ensure patient adherence to treatment. Efficacy as well as side-effect profile are, therefore, the major selection criteria when choosing an antipsychotic medication.

Entities:  

Year:  2004        PMID： 21197371      PMCID： PMC3012612     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN： 1550-5952


  23 in total

Review 1.  Pharmacologic treatment of schizophrenia.

Authors:  J M Kane
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

Review 2.  Management of weight gain in patients with schizophrenia.

Authors:  Ralph Aquila
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

3.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

Review 4.  Pharmacological prevention of relapse.

Authors:  M Lader
Journal:  Kaohsiung J Med Sci       Date:  1998-07       Impact factor: 2.744

5.  Agranulocytosis during clozapine therapy.

Authors:  Péter Gaszner; Zoltán Makkos; Piroska Kosza
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-04       Impact factor: 5.067

Review 6.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Glucose intolerance with atypical antipsychotics.

Authors:  Karin Hedenmalm; Staffan Hägg; Malin Ståhl; Orjan Mortimer; Olav Spigset
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Antipsychotics and QT prolongation.

Authors:  D M Taylor
Journal:  Acta Psychiatr Scand       Date:  2003-02       Impact factor: 6.392

9.  Obesity among adults with disabling conditions.

Authors:  Evette Weil; Melissa Wachterman; Ellen P McCarthy; Roger B Davis; Bonnie O'Day; Lisa I Iezzoni; Christina C Wee
Journal:  JAMA       Date:  2002-09-11       Impact factor: 56.272

Review 10.  Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.

Authors:  U Halbreich; B J Kinon; J A Gilmore; L S Kahn
Journal:  Psychoneuroendocrinology       Date:  2003-01       Impact factor: 4.905
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.